IQVIA Holdings Inc (IQV)vsENDRA Life Sciences Inc (NDRA)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
NDRA
ENDRA Life Sciences Inc
$3.75
+8.38%
HEALTHCARE · Cap: $4.06M
Smart Verdict
WallStSmart Research — data-driven comparison
IQV leads profitability with a 8.3% profit margin vs 0.0%. NDRA trades at a lower P/E of 0.2x. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
NDRA
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Margin of Safety
+97.3%
Fair Value
$132.74
Current Price
$3.75
$128.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Attractively priced relative to earnings
Areas to Watch
Distress zone — elevated risk
Trading at 17.0x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : NDRA
The strongest argument for NDRA centers on P/E Ratio.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : NDRA
The primary concerns for NDRA are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 3.07 is elevated, increasing financial risk.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
IQV is growing revenue faster at 10.3% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IQV scores higher overall (72/100 vs 17/100) and 10.3% revenue growth. NDRA offers better value entry with a 97.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
ENDRA Life Sciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?